FSH: What Your Number Changes About Your Treatment

What FSH Actually Measures

FSH is produced by gonadotroph cells in the anterior pituitary and released in pulses coordinated by gonadotropin-releasing hormone (GnRH) from the hypothalamus. Its job is to stimulate follicular growth in the ovary and Sertoli cell function in the testis. When the gonads work well, estradiol (in women) and inhibin B (in both sexes) provide negative feedback that keeps FSH suppressed. When the gonads underperform, that feedback disappears and FSH rises.

The Endocrine Society's 2015 guideline on primary ovarian insufficiency defines the FSH elevation threshold for POI diagnosis as two values above 25 mIU/mL drawn at least four weeks apart in a woman under 40.

Why the Feedback Loop Matters Clinically

High FSH means the pituitary is shouting because the gonads are not answering. Low FSH means the pituitary is quiet, either because feedback is intact, or because something upstream (hypothalamus, pituitary tumor, exogenous androgen) has silenced GnRH secretion.

That distinction drives the treatment fork. High FSH with low estradiol or low testosterone = primary failure, so replacement hormone is the logical answer. Low FSH with low sex hormones = secondary failure, where stimulation with gonadotropins or clomiphene may restore function rather than simply replacing the end product.

The Pulsatile Release Problem

FSH is not secreted at a steady rate. Pulses occur roughly every 90 minutes. A single draw can therefore misrepresent the mean. For cycle-day-3 testing in women, most fertility clinics collect the sample between days 2 and 4 of menstrual bleeding, and the American Society for Reproductive Medicine (ASRM) committee opinion on ovarian reserve testing recommends interpreting day-3 FSH alongside estradiol, anti-Müllerian hormone (AMH), and antral follicle count rather than relying on FSH alone.

Normal FSH Ranges and Why They Are Phase-Specific

A single "normal range" for FSH is clinically incomplete. The value shifts by menstrual phase, age, and sex, and comparing a luteal-phase draw to a follicular-phase reference range produces a meaningless result.

Reference intervals from the Mayo Clinic Laboratories compendium and validated by the Endocrine Society are widely used:

| Population | Phase / Status | Reference Range | |---|---|---| | Women | Follicular (days 1 to 9) | 3.5 to 12.5 mIU/mL | | Women | Ovulatory surge | 4.7 to 21.5 mIU/mL | | Women | Luteal (days 15 to 28) | 1.7 to 7.7 mIU/mL | | Women | Postmenopausal | 25.8 to 134.8 mIU/mL | | Men | Adult | 1.5 to 12.4 mIU/mL |

Day-3 FSH as an Ovarian Reserve Proxy

Day-3 FSH above 10 mIU/mL is associated with diminished ovarian reserve and lower IVF success rates, though the ASRM notes that the predictive threshold varies by laboratory assay. The ASRM practice committee document on ovarian reserve testing (2015) states: "Basal FSH levels >10 mIU/mL (depending on the assay) are associated with decreased pregnancy rates with IVF."

Why Estradiol Must Be Drawn Simultaneously

An estradiol value above 60 to 80 pg/mL on day 3 can suppress FSH into a falsely normal range even when follicular reserve is low. That suppressed FSH misleads the clinician into thinking the ovary is healthy. Ordering FSH without a concurrent estradiol on day 3 is an incomplete workup.

High FSH: What It Signals and How It Changes Treatment

An elevated FSH narrows the differential considerably. The pituitary is compensating for inadequate gonadal output. Treatment depends on whether that inadequacy is permanent or correctable.

FSH >40 mIU/mL in Women: Menopause and POI

The Endocrine Society Clinical Practice Guideline on menopause (2015) specifies that FSH consistently above 40 mIU/mL, confirmed on two draws at least four to six weeks apart, is diagnostic of menopause in women over 45. In women under 40, the same pattern meets criteria for primary ovarian insufficiency (POI).

Treatment diverges based on age. Postmenopausal women (over 45) who have vasomotor symptoms are candidates for menopausal hormone therapy (MHT) with estradiol plus progestogen if the uterus is intact. The USPSTF 2022 statement on hormone therapy notes that MHT is appropriate for vasomotor symptom management but does not endorse it for primary prevention of chronic conditions.

Women under 40 with POI require higher-dose hormone replacement, because physiologic estrogen deficiency at that age carries cardiovascular and bone-density consequences beyond those seen at natural menopause. The Endocrine Society guideline specifies that estrogen doses sufficient to mimic normal premenopausal levels should be used until the average age of natural menopause (approximately 51).

Day-3 FSH Between 10 and 20 mIU/mL: The Fertility Gray Zone

This range does not confirm or exclude fertility. It signals reduced ovarian reserve but does not prevent pregnancy. The practical treatment change here is intensity: clinicians shift from expectant management to earlier referral for assisted reproduction. Controlled ovarian stimulation protocols may use higher starting doses of injectable FSH (e.g., follitropin alfa, starting at 225 to 300 IU/day rather than 150 IU/day) to recruit an adequate follicle cohort.

Elevated FSH in Men: Primary Hypogonadism

In men with low testosterone and FSH above the upper reference limit (roughly 7.6 to 12.4 mIU/mL depending on assay), the problem lies in the testes, not the pituitary. This pattern, called hypergonadotropic hypogonadism, is seen in Klinefelter syndrome (47,XXY), post-chemotherapy gonadal damage, and varicocele-related seminiferous tubule failure.

The Endocrine Society male hypogonadism guideline (2018) states: "In men with primary hypogonadism, testosterone therapy is indicated to restore serum testosterone to the mid-normal range and to ameliorate symptoms and signs of androgen deficiency."

Critically, testosterone replacement suppresses FSH further and does not rescue spermatogenesis. Men with primary hypogonadism who want fertility preservation cannot simply start TRT. They require specialist counseling about sperm banking before treatment begins.

Low FSH: What It Signals and How It Changes Treatment

Low or inappropriately normal FSH in the context of low sex hormones points upstream. The gonad may be capable of working but is not receiving adequate stimulation.

Hypothalamic Amenorrhea in Women

Functional hypothalamic amenorrhea (FHA) is defined by the absence of menstruation, low or low-normal FSH, low LH, and low estradiol in the absence of organic pathology. The Endocrine Society clinical practice guideline on FHA (2017) identifies energy deficiency, psychological stress, and excessive exercise as the three main drivers.

FSH in FHA is typically below 5 mIU/mL, sometimes below 2 mIU/mL. The guideline explicitly states that exogenous estrogen therapy alone does not address the underlying cause and may mask bone loss progression without resolving the hypothalamic suppression. The first-line treatment is correction of the energy deficit, reduction of training load, and cognitive behavioral therapy, not hormone replacement.

Secondary Hypogonadism in Men

Low testosterone with FSH below 1.5 mIU/mL in a man indicates hypogonadotropic hypogonadism. Causes include exogenous anabolic steroid or testosterone use, hyperprolactinemia, hemochromatosis, pituitary adenoma, and idiopathic hypogonadotropic hypogonadism (IHH).

This diagnosis changes the entire treatment algorithm. Simply starting testosterone will suppress the pituitary further, eliminate any residual testicular function, and cause testicular atrophy. For men who want to preserve fertility, the Endocrine Society 2018 guideline recommends gonadotropin therapy with human chorionic gonadotropin (hCG) plus follitropin alfa or beta. HCG mimics LH and drives intratesticular testosterone production. FSH analogs then stimulate Sertoli cells to support spermatogenesis.

For men not concerned with fertility, clomiphene citrate (an off-label but commonly used selective estrogen receptor modulator) or enclomiphene blocks negative feedback at the pituitary, raises endogenous LH and FSH, and subsequently increases testicular testosterone output. This approach preserves testicular size and some spermatogenic function, unlike exogenous TRT.

Exogenous Androgen Suppression

Men using anabolic steroids or testosterone without supervision routinely present with suppressed FSH (often undetectable) and LH, alongside low endogenous testosterone because the exogenous source is not detected by standard immunoassays for testosterone. The clinical picture is obvious once FSH and LH are drawn together. Recovery of the HPG axis after cessation of exogenous androgens takes three to six months in most cases, though some men experience prolonged suppression lasting beyond twelve months. Post-cycle recovery protocols using hCG, clomiphene, or tamoxifen are not FDA-approved for this indication but are used clinically and discussed in the Endocrine Society position statement on exogenous androgens.

FSH in Perimenopause: Why One Number Is Never Enough

Perimenopause is the transition phase during which ovarian reserve declines but menstruation has not yet ceased for 12 consecutive months. FSH during perimenopause is erratic. A single draw may show FSH of 22 mIU/mL one month and 8 mIU/mL three months later.

The Endocrine Society's 2015 menopause guideline explicitly advises against relying on a single FSH measurement to confirm menopause in women under 45 who are still experiencing menstrual cycles, regardless of how elevated that single value appears.

Serial Testing Protocol

Two FSH values drawn four to six weeks apart, both above 40 mIU/mL, with 12 months of amenorrhea, confirm menopause. Clinicians who jump to hormone therapy after a single high FSH may initiate treatment prematurely. Conversely, clinicians who dismiss vasomotor symptoms because one FSH was "only" 18 mIU/mL may withhold treatment from a woman in early menopause.

FSH and Hormonal Contraception Decisions

Women in perimenopause using combined oral contraceptives (COCs) cannot be assessed by FSH. The exogenous estrogen in COCs suppresses FSH to undetectable levels, masking the underlying menopausal transition. The ACOG practice bulletin on contraception in perimenopause recommends stopping COCs for two to three months and drawing FSH and AMH if the clinical question is whether a woman has reached menopause and can discontinue contraception.

How FSH Directs Specific Drug Choices

The table below summarizes how a given FSH result maps to a treatment decision. This framework is not a substitute for full clinical evaluation, but it shows the decision branches that FSH opens or closes.

| FSH Pattern | Sex | Probable Diagnosis | Treatment Direction | |---|---|---|---| | >40 mIU/mL (x2) | Female >45 | Menopause | MHT (estradiol plus progestogen if uterus intact) | | >25 mIU/mL (x2) | Female <40 | POI | High-dose physiologic estrogen until age 51 | | 10 to 20 mIU/mL day 3 | Female | Diminished ovarian reserve | Earlier ART referral, higher FSH stimulation doses | | <2 mIU/mL | Female | FHA or hypothalamic suppression | Treat root cause first; estrogen alone insufficient | | >8 mIU/mL + low T | Male | Primary hypogonadism | TRT after fertility counseling and sperm banking | | <1.5 mIU/mL + low T | Male | Secondary hypogonadism | Gonadotropins (hCG + FSH analog) if fertility desired; clomiphene if not | | Undetectable | Male | Exogenous androgen suppression | Cease exogenous androgens; monitor HPG recovery |

Gonadotropin Dosing When FSH Is the Target

When FSH is used therapeutically (as injectable gonadotropins for ovulation induction or spermatogenesis), the starting dose and titration schedule depend on the baseline FSH level and the clinical indication. A Cochrane review on gonadotropin protocols for IVF (2018) covering 34 trials found no statistically significant difference in live birth rates between long GnRH agonist protocols using 150 IU versus 225 IU recombinant FSH as a starting dose in normal responders, but poor responders (often identified partly by elevated baseline FSH) showed better outcomes with higher starting doses.

Monitoring FSH During TRT

Once testosterone replacement begins in men with primary hypogonadism, FSH monitoring becomes less actionable because exogenous testosterone will suppress the HPG axis regardless of underlying testicular status. The Endocrine Society 2018 guideline recommends monitoring testosterone, hematocrit, PSA, and bone density in men on TRT, not serial FSH, because FSH adds little information once androgen replacement is established and fertility is not a concern.

When to Retest FSH and What Changes the Number

FSH is not static. Several physiologic and pharmacologic factors shift it.

Factors That Raise FSH

• Menopause or POI: Progressive loss of follicular pool removes inhibin B and estradiol feedback. FSH rises steadily, often reaching 80 to 120 mIU/mL in the first postmenopausal years before stabilizing.
• GnRH agonist flare: The initial agonist phase of a GnRH agonist (leuprolide, triptorelin) causes a transient FSH and LH surge before downregulation occurs.
• Clomiphene citrate: Blocks estrogen receptors in the pituitary, reducing negative feedback. FSH rises within seven to ten days of a standard 50 mg course.

Factors That Lower FSH

• Exogenous estrogen: Even low-dose topical estradiol can suppress FSH. A woman using 0.025 mg estradiol patches may show an FSH of 12 mIU/mL rather than her true postmenopausal 85 mIU/mL.
• Exogenous androgens: Testosterone, DHEA at high doses, and anabolic steroids all suppress GnRH pulsatility and reduce FSH.
• Hyperprolactinemia: Elevated prolactin (from a lactotroph adenoma or dopamine-blocking medications) suppresses GnRH and secondarily lowers FSH. A prolactin level should be drawn alongside FSH whenever secondary hypogonadism is suspected.
• Pregnancy: Rising hCG suppresses FSH to near-undetectable levels throughout gestation.

Retesting Intervals by Clinical Context

For perimenopause confirmation, the standard is two draws four to six weeks apart. For post-TRT cessation monitoring of HPG axis recovery, retesting every three months is practical because FSH recovery lags LH recovery by four to eight weeks. For FHA management, retesting FSH every three to four months after lifestyle intervention tracks hypothalamic recovery. A rising FSH toward the normal follicular-phase range (3.5 to 12.5 mIU/mL) alongside returning LH pulsatility confirms that the axis is recovering.

What FSH Does Not Tell You

FSH is a powerful but incomplete signal. Three common misreadings:

Normal FSH does not guarantee fertility. A 38-year-old woman with FSH of 7 mIU/mL may have very few remaining follicles. AMH and antral follicle count capture the quantitative reserve that FSH misses. The ASRM committee opinion (2015) states clearly that FSH should not be used as a standalone test for ovarian reserve assessment.

High FSH does not eliminate pregnancy chances. Women with FSH between 15 and 30 mIU/mL have conceived spontaneously and through IVF, though success rates are lower. A single cycle with elevated FSH is not a definitive statement about all future cycles.

FSH does not diagnose polycystic ovary syndrome (PCOS). PCOS is defined by Rotterdam criteria: oligo-ovulation, clinical or biochemical androgen excess, and polycystic ovarian morphology on ultrasound. The LH/FSH ratio (often above 2:1 in PCOS) is sometimes used as a supporting finding, but the Androgen Excess and PCOS Society guidelines do not include FSH as a required diagnostic criterion.